Literature DB >> 11672825

Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?

M U Mondelli1, A Cerino, L Segagni, A Meola, A Cividini, E Silini, A Nicosia.   

Abstract

The hypervariable region 1 (HVR1) of the E2 protein of hepatitis C virus (HCV) is highly heterogeneous and is responsible for significant inter- and intra-individual variation of the infecting virus, which may represent an important pathogenetic mechanism leading to escape and persistent infection. Moreover, a binding site for neutralizing antibodies (Ab) has been allegedly identified in this region. Prospective studies of serological responses to synthetic oligopeptides derived from HVR1 sequences of patients with acute and chronic HCV infection showed extensive serological cross-reactivity for unrelated HVR1 peptides in the majority of the patients. A significant correlation was found between HVR1 sequence variation, and intensity, and cross-reactivity of humoral immune responses providing strong evidence in support of the contention that HCV variant selection is driven by the host immune pressure. Monoclonal Ab (mAb) generated following immunization of mice with peptides derived from natural HVR1 sequences also showed cross-reactivity for several HVR1 sequences attesting to the existence of conserved amino acid motifs among different variants. These findings suggest that it is possible to induce a broadly cross-reactive immune response to HVR1 and that this mechanism can be used to generate protective immunity for a large repertoire of HCV variants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672825     DOI: 10.1016/s0166-3542(01)00180-2

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  22 in total

Review 1.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

Review 2.  Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus.

Authors:  Ashraf Tabll; Aymn T Abbas; Sherif El-Kafrawy; Ahmed Wahid
Journal:  World J Hepatol       Date:  2015-10-08

3.  An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.

Authors:  Birke Bartosch; Géraldine Verney; Marlène Dreux; Peggy Donot; Yoann Morice; François Penin; Jean-Michel Pawlotsky; Dimitri Lavillette; Francois-Loïc Cosset
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Evaluation of cross-reactive antibody response to HVR1 in chronic hepatitis C.

Authors:  Bing-Shui Xiu; Xiao-Yan Feng; Jing He; Guo-Hua Wang; Xiang-Ying Zhang; He-Qiu Zhang; Xiao-Guo Song; Kun Chen; Shi-Gan Ling; Cui-Xia Zhu; Lai Wei; Hui-Ying Rao
Journal:  World J Gastroenterol       Date:  2010-09-21       Impact factor: 5.742

5.  Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.

Authors:  Emmanuel Fenouillet; Dimitri Lavillette; Silvia Loureiro; George Krashias; Guillemette Maurin; François-Loïc Cosset; Ian M Jones; Rym Barbouche
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

6.  High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy.

Authors:  Xiaofeng Fan; Qing Mao; Donghui Zhou; Yang Lu; Jianwei Xing; Yanjuan Xu; Stuart C Ray; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

7.  Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates.

Authors:  Sook-Hyang Jeong; Ming Qiao; Michelina Nascimbeni; Zongyi Hu; Barbara Rehermann; Krishna Murthy; T Jake Liang
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study.

Authors:  Jeff Fairman; Joseph Moore; Mathieu Lemieux; Koen Van Rompay; Yongzhi Geng; John Warner; Kristina Abel
Journal:  Hum Vaccin       Date:  2009-03-14

9.  Coordinated evolution of the hepatitis C virus.

Authors:  D S Campo; Z Dimitrova; R J Mitchell; J Lara; Y Khudyakov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-09       Impact factor: 11.205

10.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus.

Authors:  Elisa Scarselli; Helenia Ansuini; Raffaele Cerino; Rosa Maria Roccasecca; Stefano Acali; Gessica Filocamo; Cinzia Traboni; Alfredo Nicosia; Riccardo Cortese; Alessandra Vitelli
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.